-
Surrogate BBB Model for CNS Permeability Screening
2026-09-10
Hu and colleagues developed a high-throughput LLC-PK1-MOCK/MDR1 Transwell model that links directional permeability measurements with unbound brain-to-plasma distribution. Its integration of P-glycoprotein activity and lysosomal trapping correction improves interpretation of screening data and supports earlier CNS candidate prioritization.
-
PD 173074 Workflows for FGFR1 Signaling Research
2026-09-10
PD 173074 enables concentration-matched interrogation of FGFR1 and VEGFR2 in kinase, cancer-cell, angiogenesis, and resistance models. Its strongest use is as a mechanistic probe paired with pathway biomarkers, genetic context, and carefully controlled exposure conditions.
-
KX2-391 as an HBV Transcription Inhibitor
2026-09-09
Harada and colleagues used a recombinant NanoLuc-reporting HBV system to identify KX2-391 as a small-molecule inhibitor of HBV transcription. Their experiments linked the antiviral phenotype to inhibition of tubulin polymerization rather than Src kinase suppression, providing a mechanistic basis for repurposing this scaffold in HBV research.
-
CSBTA Pharmacokinetics in MASH Mice
2026-09-09
The reference study integrates plasma pharmacokinetics, tissue distribution, cellular uptake, and enzyme–transporter analysis to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings show disease-state-dependent accumulation of dehydrocavidine, palmatine, and berberine, providing a mechanistic basis for exposure-aware dosing research in MASLD/MASH.
-
4-PBA: Turning ER Stress Into Causal Evidence
2026-09-08
4-Phenylbutyric acid is most valuable when used not simply to suppress stress markers, but to test whether proteostasis disruption causally drives autophagic cell death. This thought-leadership guide translates recent liver cancer evidence into a rigorous workflow for ER stress alleviation, pathway validation, and translational decision-making.
-
BRD4770: A G9a Inhibitor for Causal Epigenetics
2026-09-08
BRD4770 is a G9a histone methyltransferase inhibitor for linking H3K9 methylation changes to senescence and cancer-cell phenotypes. This article provides an assay-centered framework for interpreting BRD4770 data across PANC-1 models and the c-MYC–G9a axis described in breast cancer research.
-
Omeprazole A2845: Research Protocol Guidance
2026-09-07
Omeprazole (A2845) is a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and antiulcer activity studies. This guidance covers solvent selection, assay setup, storage, and quality control; the material is for scientific research only and should not be used for diagnostic, therapeutic, or medical applications.
-
4-Ethylphenyl Sulfate: Applied Research Workflows
2026-09-07
4-Ethylphenyl sulfate connects renal biomarker measurement, gut microbiota-brain interaction research, and controlled surface-adsorption experiments in one defined metabolite workflow. This guide provides practical handling, assay-design, and troubleshooting strategies for reproducible studies across renal dysfunction and autism spectrum disorder models.
-
Trelagliptin succinate: Adipocyte Assay Workflows
2026-09-05
Build more informative diabetes mellitus research workflows with Trelagliptin succinate, from DPP-4 activity testing to PI3K/AKT/GLUT4 analysis in insulin-resistant adipocytes. The guide connects assay design, formulation control, pathway readouts, and troubleshooting with evidence from a focused reference study.
-
Omeprazole (A2845): Research Workflow Guide
2026-09-04
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for gastric acid secretion research, with dossier-reported activity, solubility, identity, and storage specifications. It is suitable for controlled in vitro and preclinical research workflows, but not for diagnostic, medical, or clinical use and should not be assigned dosing claims without matched evidence.
-
Hexa His Tag Peptide: Assay Design Beyond Elution
2026-09-04
Hexa His tag peptide enables clean, competitive release of His-tagged proteins from antibody-based immunoprecipitation. This article connects its chemistry to assay architecture, protein interaction analysis, and mechanistic lessons from a 2026 CARMIL–actin study.
-
Cy5 TSA Fluorescence System Kit Workflow
2026-09-03
The Cy5 TSA Fluorescence System Kit converts localized HRP activity into a bright, covalently deposited Cy5 signal for difficult ICC, IHC, and FISH targets. This practical guide connects the assay to resibufogenin–NLRP3 atherosclerosis research, with optimization steps for tissue imaging, low-abundance biomarkers, and multiplex-compatible workflows.
-
U-73122: From PLC Inhibition to Invasion Assays
2026-09-03
U-73122 is a phospholipase C inhibitor for connecting calcium signaling with inflammatory responses and cancer-cell motility. This guide focuses on mechanistic assay design, interpretation, and the evidence linking PLC perturbation to myosin light-chain phosphorylation.
-
PAD4, NETs, and Translational Strategy
2026-09-02
A mechanistic and strategic guide to using Cl-Amidine as a PAD4 probe across NET biology, cancer research, inflammatory disease, and septic shock models.
-
T7 RNA Polymerase: From Template to RNA Function
2026-09-02
T7 RNA Polymerase enables precise, promoter-directed RNA synthesis for research workflows. This article connects template design and RNA quality control with lessons from inhaled RNA immunotherapy research, offering a practical framework beyond conventional protocol optimization.